

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
19 May 2005 (19.05.2005)

PCT

(10) International Publication Number
WO 2005/044260 A1

(51) International Patent Classification⁷: **A61K 31/404**,
31/428, 31/426, 31/4709, 31/498, A61P 11/02, 11/06,
17/00, 19/02, 37/00, 43/00

(74) Agents: **ROBERTS, Alison, Christine** et al.; Kilburn &
Strode, 20 Red Lion Street, London WC1R 4PJ (GB).

(21) International Application Number:
PCT/GB2004/004417

(22) International Filing Date: 19 October 2004 (19.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0324763.2 23 October 2003 (23.10.2003) GB

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **OXAGEN LIMITED** [GB/GB]; 91 Milton Park, Abingdon, Oxon OX14 4RY (GB).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **MIDDLEMISS, David** [GB/GB]; 62 Thorley Hill, Bishop's Stortford, Herts CM23 3NF (GB). **ASHTON, Mark, Richard** [GB/GB]; Evotec OAI Limited, 151 Milton Park, Abingdon, Oxon OX14 4RY (GB). **BOYD, Edward, Andrew** [GB/GB]; Evotec OAI Limited, 151 Milton Park, Abingdon, Oxon OX14 4RY (GB). **BROOKFIELD, Frederick, Arthur** [GB/GB]; Evotec OAI Limited, 151 Milton Park, Abingdon, Oxon OX14 4RY (GB).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF CRTH2 ANTAGONIST COMPOUNDS IN THERAPY



(I)

(57) **Abstract:** Compounds of general formula (I) wherein R^1 , R^2 , R^3 and R^4 are independently hydrogen, halo, C_1 - C_6 alkyl, $-O(C_1$ - C_6 alkyl), $-\text{CON}(R^{11})_2$, $-\text{SO}^{11}$, $-\text{SO}_2R^{11}$, $-\text{SO}_2\text{N}(R^{11})_2$, $-\text{N}(R^{11})_2$, $-\text{NR}^{11}\text{COR}^{11}$, $-\text{CO}_2R^{11}$, $-\text{COR}^{11}$, $-\text{SR}^{11}$, $-\text{OH}$, $-\text{NO}_2$ or $-\text{CN}$; each R^{11} is independently hydrogen or C_1 - C_6 alkyl; R^5 and R^6 are each independently hydrogen, or C_1 - C_6 alkyl or together with the carbon atom to which they are attached form a C_3 - C_7 cycloalkyl group; R^7 is hydrogen or C_1 - C_6 alkyl; R^8 is an aromatic moiety optionally substituted with one or more substituents selected from halo, C_1 - C_6 alkyl, $-O(C_1$ - C_6)alkyl, $-\text{CON}(R^{11})_2$, $-\text{SOR}^{11}$, $-\text{SO}_2R^{11}$, $-\text{SO}_2\text{N}(R^{11})_2$, $-\text{N}(R^{11})_2$, $-\text{NR}^{11}\text{COR}^{11}$, $-\text{CO}_2R^{11}$, $-\text{COR}^{11}$, $-\text{SR}^{11}$, $-\text{OH}$, $-\text{NO}_2$ or $-\text{CN}$; wherein R^{11} is as defined above; R^9 is hydrogen, or C_1 - C_6 alkyl; provided that: R^8 is not phenyl substituted with $-\text{COOH}$; when any two of R^1 , R^2 , R^3 and R^4 are hydrogen, neither of the other two of R^1 , R^2 , R^3 and R^4 is C_3 - C_6 alkyl; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in the preparation of pharmaceuticals for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.

WO 2005/044260 A1

USE OF CRTH2 ANTAGONIST COMPOUNDS IN THERAPY

The present invention relates to the use of certain compounds in the treatment and prevention of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis and other inflammatory diseases mediated by prostaglandin D₂ (PGD₂) acting at the CRTH2 receptor on cells including eosinophils, basophils and Th2 lymphocytes.

PGD₂ is an eicosanoid, a class of chemical mediator synthesised by cells in response to local tissue damage, normal stimuli or hormonal stimuli or *via* cellular activation pathways. Eicosanoids bind to specific cell surface receptors on a wide variety of tissues throughout the body and mediate various effects in these tissues. PGD₂ is known to be produced by mast cells, macrophages and Th2 lymphocytes and has been detected in high concentrations in the airways of asthmatic patients challenged with antigen (Murray *et al*, (1986), *N. Engl. J. Med.* **315**: 800-804). Instillation of PGD₂ into airways can provoke many features of the asthmatic response including bronchoconstriction (Hardy *et al*, (1984) *N. Engl. J. Med.* **311**: 209-213; Sampson *et al*, (1997) *Thorax* **52**: 513-518) and eosinophil accumulation (Emery *et al*, (1989) *J. Appl. Physiol.* **67**: 959-962).

The potential of exogenously applied PGD₂ to induce inflammatory responses has been confirmed by the use of transgenic mice overexpressing human PGD₂ synthase which exhibit exaggerated eosinophilic lung inflammation and Th2 cytokine production in response to antigen (Fujitani *et al*, (2002) *J. Immunol.* **168**: 443-449).

The first receptor specific for PGD₂ to be discovered was the DP receptor which is linked to elevation of the intracellular levels of cAMP. However, PGD₂ is thought to mediate much of its proinflammatory activity through interaction with a G protein-coupled receptor termed CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2 cells) which is expressed by Th2 lymphocytes, eosinophils and basophils (Hirai *et al*, (2001) *J. Exp. Med.* **193**: 255-261, and EP0851030 and EP-A-1211513 and Bauer *et al*, EP-A-1170594). It seems clear that the effect of PGD₂ on

the activation of Th2 lymphocytes and eosinophils is mediated through CRTH2 since the selective CRTH2 agonists 13,14 dihydro-15-keto-PGD₂ (DK-PGD₂) and 15R-methyl-PGD₂ can elicit this response and the effects of PGD₂ are blocked by an anti-CRTH2 antibody (Hirai *et al*, 2001; Monneret *et al*, (2003) *J. Pharmacol. Exp. Ther.* **304**: 349-355). In contrast, the selective DP agonist BW245C does not promote migration of Th2 lymphocytes or eosinophils (Hirai *et al*, 2001; Gervais *et al*, (2001) *J. Allergy Clin. Immunol.* **108**: 982-988). Based on this evidence, antagonising PGD₂ at the CRTH2 receptor is an attractive approach to treat the inflammatory component of Th2-dependent allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.

EP-A-1170594 suggests that the method to which it relates can be used to identify compounds which are of use in the treatment of allergic asthma, atopic dermatitis, allergic rhinitis, autoimmune disease, reperfusion injury and a number of inflammatory conditions, all of which are mediated by the action of PGD₂ at the CRTH2 receptor.


Compounds which bind to CRTH2 are taught in WO-A-03066046 and WO-A-03066047. These compounds are not new but were first disclosed, along with similar compounds, in GB 1356834, GB 1407658 and GB 1460348, where they were said to have anti-inflammatory, analgesic and antipyretic activity. WO-A-03066046 and WO-A-03066047 teach that the compounds to which they relate are modulators of CRTH2 receptor activity and are therefore of use in the treatment or prevention of obstructive airway diseases such as asthma, chronic obstructive pulmonary disease (COPD) and a number of other diseases including various conditions of bones and joints, skin and eyes, GI tract, central and peripheral nervous system and other tissues as well as allograft rejection.

PL 65781 and JP 43-24418 also relate to indole derivatives which are similar in structure to indomethacin and, like indomethacin, are said to have anti-inflammatory and antipyretic activity. Thus, although this may not have been appreciated at the

time when these documents were published, the compounds they describe are COX inhibitors, an activity which is quite different from that of the compounds of the present invention. Indeed, COX inhibitors are contraindicated in the treatment of many of the diseases and conditions, for example asthma and inflammatory bowel disease for which the compounds of the present invention are useful, although they may sometimes be used to treat arthritic conditions.

We have now discovered that certain indole derivatives in which the indole nitrogen is substituted with a carboxylic acid moiety` are antagonists of PGD₂ at the CRTH2 receptor and are useful in a method for the treatment of diseases and conditions mediated by PGD₂ at the CRTH2 receptor, the method comprising administering to a patient in need of such treatment a suitable amount of one of the compounds.

Therefore, in a first aspect of the invention, there is provided the use of a compound of general formula (I):



I

wherein

R¹, R², R³ and R⁴ are independently hydrogen, halo, C₁-C₆ alkyl, -O(C₁-C₆ alkyl), -CON(R¹¹)₂, -SOR¹¹, -SO₂R¹¹, -SO₂N(R¹¹)₂, -N(R¹¹)₂, -NR¹¹COR¹¹, -CO₂R¹¹, -COR¹¹, -SR¹¹, -OH, -NO₂ or -CN;

each R¹¹ is independently hydrogen or C₁-C₆ alkyl;

R⁵ and R⁶ are each independently hydrogen, or C₁-C₆ alkyl or together with the carbon atom to which they are attached form a C₃-C₇ cycloalkyl group;

R⁷ is hydrogen or C₁-C₆ alkyl;

R⁸ is an aromatic moiety optionally substituted with one or more substituents

selected from halo, C₁-C₆ alkyl, -O(C₁-C₆)alkyl, -CON(R¹¹)₂, -SOR¹¹, -SO₂R¹¹, -SO₂N(R¹¹)₂, -N(R¹¹)₂, -NR¹¹COR¹¹, -CO₂R¹¹, -COR¹¹, -SR¹¹, -OH, -NO₂ or -CN;

wherein R¹¹ is as defined above;

R⁹ is hydrogen, or C₁-C₆ alkyl;

5 provided that:

R⁸ is not phenyl substituted with -COOH;

when any two of R¹, R², R³ and R⁴ are hydrogen, neither of the other two of R¹, R², R³ and R⁴ is C₃-C₆ alkyl;

or a pharmaceutically acceptable salt, hydrate, solvate, complex or prodrug thereof;

10 in the preparation of an agent for the treatment or prevention of allergic asthma, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity (including contact dermatitis), conjunctivitis, especially allergic conjunctivitis, eosinophilic bronchitis, food allergies, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis and Crohn's disease, mastocytosis and
15 also other PGD₂-mediated diseases, for example autoimmune diseases such as hyper IgE syndrome and systemic lupus erythematus, psoriasis, acne, multiple sclerosis, allograft rejection, reperfusion injury, chronic obstructive pulmonary disease, as well as, in some cases, rheumatoid arthritis, psoriatic arthritis and osteoarthritis.

20 WO-A-9950268, WO-A-0032180, WO-A-0151849 and WO-A-0164205 all relate to compounds which are similar to the compounds of general formula (I). However, these compounds are said to be aldose reductase inhibitors useful in the treatment of diabetes mellitus (WO-A-9950268, WO-A-0032180 and WO-A-0164205) or hypouricemic agents (WO-A-0151849). There is no suggestion in any of these
25 documents that the compounds would be useful for the treatment of diseases and conditions mediated by PGD₂ at the CRTH2 receptor. The preferred compounds described in these prior art documents mostly have a benzothiazole substituent in the position equivalent to R⁸ of general formula (I).

30 US 4,363,912 relates to compounds similar to those of the present invention which are said to be inhibitors of thromboxane synthetase and to be useful in the treatment

of conditions such as thrombosis, ischaemic heart disease and stroke. The compounds have a pyridyl group in the position equivalent to R⁸ of general formula (I).

- 5 WO-A-9603376 relates to compounds which are said to be sPLA₂ inhibitors which are useful in the treatment of bronchial asthma and allergic rhinitis. These compounds all have amide or hydrazide substituents in place of the carboxylic acid derivative of the compounds of the present invention.
- 10 JP 2001247570 relates to a method of producing a 3-benzothiazolylmethyl indole acetic acid, which is said to be an aldose reductase inhibitor.

US 4,859,692 relates to compounds which are said to be leukotriene antagonists useful in the treatment of conditions such as asthma, hay fever and allergic rhinitis as well as certain inflammatory conditions such as bronchitis, atopic and ectopic eczema. The compounds of this document are similar to the compounds of general formula (I), but general formula (I) specifically excludes compounds in which R⁸ is phenyl substituted with a –COOH group, which is the only area of overlap. Furthermore, *J. Med. Chem.*, **6(33)**, 1781-1790 (1990), which has the same authors

15 as this prior patent application, teaches that compounds with an acetic acid group on the indole nitrogen do not have significant peptidoleukotriene activity. In view of this, it is most surprising that the compounds of the present invention, which all have an acetic acid group on the indole nitrogen, are useful for treating conditions such as asthma, hay fever and allergic rhinitis.

25

US 4,273,782 is directed to compounds similar to those of general formula (I), which are said to be useful in the treatment of conditions such as thrombosis, ischaemic heart disease, stroke, transient ischaemic attack, migraine and the vascular complications of diabetes. There is no mention in the document of conditions

30 mediated by the action of PGD₂ at the CRTH2 receptor. The compounds of this prior art document all have an imidazole group in the position equivalent to R⁸ of

general formula (I).

US 3,557,142 relates to 3-substituted-1-indole carboxylic acids and esters which are said to be useful in the treatment of inflammatory conditions.

5

WO-A-03/097598 relates to compounds which are CRTH2 receptor antagonists. They do not have an aromatic substituent in the position equivalent to R⁸ of general formula (I).

10 Cross *et al*, *J. Med. Chem.* **29**, 342-346 (1986) relates to a process for preparing compounds similar to those of general formula (I) from the corresponding esters similar to the compounds of general formula (II). The compounds to which it relates are said to be inhibitors of thromboxane synthetase and all have an imidazole group in the position equivalent to R⁸ of general formula (I).

15

EP-A-0539117 relates to leukotriene antagonists which are similar in structure to the compounds of general formula (I).

20 US 2003/0153751 relates to compounds which are sPLA₂ inhibitors. Although the structural formula covers compounds similar to those of general formula (I), all of the exemplified compounds have bulky substituents at the 2- and 5-positions of the indole system and are therefore very different from the compounds of the present invention.

25 US 2004/011648 discloses compounds which are similar to the compounds of general formula (I) and which are inhibitors of PAI-1. There is no suggestion that the compounds might have CRTH2 antagonist activity.

30 WO 2004/058164 relates to compounds which are said to be asthma and allergic inflammation modulators. The only compounds for which activity is demonstrated are entirely different in structure from the compounds of general formula (I).

Compounds which bind to the CRTH2 receptor are disclosed in WO-A-03/097042 and WO-A-03/097598. These compounds are indole acetic acids but in WO-A-03/097042 the indole system is fused at the 2-3 positions to a 5-7 membered carbocyclic ring. In WO-A-03/097598 there is a pyrrolidine group at the indole 3-position.

WO-A-03/101981 and WO-A-03/101961 both relate to compound which are said to be CRTH2 antagonists but which differ in structure from the compounds of general formula (I) because there is an -S- or -SO₂- group linked to the indole 3-position in place of the CH₂ group of the compounds of general formula (I).

In the present specification "C₁-C₆ alkyl" refers to a straight or branched saturated hydrocarbon chain having one to six carbon atoms and optionally substituted with one or more halo substituents or with one or more C₃-C₇ cycloalkyl groups. Examples include methyl, ethyl, n-propyl, isopropyl, t-butyl, n-hexyl, trifluoromethyl, 2-chloroethyl, methylenecyclopropyl, methylenecyclobutyl and methylenecyclopentyl.

"C₁-C₄ alkyl" and "C₁-C₁₈ alkyl" have similar meanings except that they contain from one to four and from one to eighteen carbon atoms respectively.

C₃-C₇ cycloalkyl refers to a saturated 3 to 7 membered carbocyclic ring. Examples of such groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

In the present specification, "halo" refers to fluoro, chloro, bromo or iodo.

The terms "aromatic moiety" and "aryl" in the context of the present specification refer to an aromatic ring system having from 5 to 14 ring carbon atoms and containing up to three rings, one or more of which may be replaced by a nitrogen, oxygen or sulfur atom. Examples of aromatic moieties are benzene, pyridine,

naphthalene, biphenyl, quinoline, isoquinoline, quinazoline, thiazole, benzthiazole, benzoxazole, benzimidazole, indole, indazole and imidazole ring systems.

- Appropriate pharmaceutically and veterinarily acceptable salts of the compounds of general formulae (I) and (II) include basic addition salts such as sodium, potassium, calcium, aluminium, zinc, magnesium and other metal salts as well as choline, diethanolamine, ethanolamine, ethyl diamine and other well known basic addition salts.
- Where appropriate, pharmaceutically or veterinarily acceptable salts may also include salts of organic acids, especially carboxylic acids, including but not limited to acetate, trifluoroacetate, lactate, gluconate, citrate, tartrate, maleate, malate, pantothenate, adipate, alginate, aspartate, benzoate, butyrate, digluconate, cyclopentanate, glucoheptanate, glycerophosphate, oxalate, heptanoate, hexanoate, fumarate, nicotinate, pamoate, pectinate, 3-phenylpropionate, picrate, pivalate, propionate, tartrate, lactobionate, pivate, camphorate, undecanoate and succinate, organic sulfonic acids such as methanesulfonate, ethanesulfonate, 2-hydroxyethane sulfonate, camphorsulfonate, 2-naphthalenesulfonate, benzenesulfonate, p-chlorobenzenesulfonate and p-toluenesulfonate; and inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, hemisulfate, thiocyanate, persulfate, phosphoric and sulfonic acids.

Salts which are not pharmaceutically or veterinarily acceptable may still be valuable as intermediates.

- Prodrugs are any covalently bonded compounds which release the active parent drug according to general formula (I) *in vivo*. Examples of prodrugs include alkyl esters of the compounds of general formula (I), for example the esters of general formula (II) below.

- If a chiral centre or another form of isomeric centre is present in a compound of the

present invention, all forms of such isomer or isomers, including enantiomers and diastereoisomers, are intended to be covered herein. Compounds of the invention containing a chiral centre may be used as a racemic mixture, an enantiomerically enriched mixture, or the racemic mixture may be separated using well-known techniques and an individual enantiomer may be used alone.

In the compounds of general formula (I), it is preferred that, independently or in any combination:

- R^1 is halo or hydrogen;
- 10 R^2 is halo or hydrogen;
- R^3 is halo or hydrogen;
- R^4 is halo or hydrogen.

In more preferred compounds, R^1 , R^3 and R^4 are hydrogen, while R^2 is halo, particularly fluoro.

In preferred compounds of general formula (I), R^5 and R^6 are each independently hydrogen or C_1 - C_4 alkyl. However, in more active compounds, at least one, and preferably both of R^5 and R^6 are hydrogen.

20 Similarly, it is preferred that R^9 is hydrogen or C_1 - C_4 alkyl, most preferably hydrogen.

Compounds of general formula (I) preferably have an R^7 group chosen from H or C_1 - C_6 alkyl; most suitably R^7 is methyl.

In preferred compounds of general formula (I), R^8 is phenyl, naphthalenyl, quinoliny, quinoxaliny, thiazolyl, biphenyl or benzothiazolyl, any of which may optionally be substituted with one or more substituents as defined above.

30 In particular, it is preferred that R^8 is phenyl substituted at the 4-position or

naphthalen-2-yl, quinolin-2-yl, quinoxalin-2-yl, thiazol-2-yl or benzothiazol-2-yl, any of which may optionally be substituted with one or more of the substituents defined above.

- 5 When the R⁸ moiety is substituted, preferred substituents include halo, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₁-C₄ alkylsulfonyl and hydroxy.

Especially preferred substituents for the R⁸ moiety include chloro, fluoro, methyl, ethyl, t-butyl, trifluoromethyl, methoxy, methanesulfonyl and hydroxy.

10

Among the most preferred compounds are the following:

1. {3-[1-(4-Chloro-phenyl)-ethyl]-5-fluoro-2-methyl-indol-1-yl}-acetic acid
2. {5-Fluoro-2-methyl-3-[1-(4-trifluoromethyl-phenyl)-ethyl]-indol-1-yl}-acetic acid
- 15 acid
3. {3-[1-(4-*tert*-Butyl-phenyl)-ethyl]-5-fluoro-2-methyl-indol-1-yl}-acetic acid
4. {5-Fluoro-3-[1-(4-methanesulfonyl-phenyl)-ethyl]-2-methyl-indol-1-yl}-acetic acid
5. [5-Fluoro-2-methyl-3-(1-naphthalen-2-yl-ethyl)-indol-1-yl]-acetic acid
- 20 6. (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid
7. (5-Fluoro-2-methyl-3-naphthalen-2-ylmethyl-indol-1-yl)-acetic acid
8. [5-Fluoro-3-(8-hydroxy-quinolin-2-ylmethyl)-2-methyl-indol-1-yl]-acetic acid
9. (5-Fluoro-2-methyl-3-quinoxalin-2-ylmethyl-indol-1-yl)-acetic acid
10. [5-Fluoro-3-(4-methoxy-benzyl)-2-methyl-indol-1-yl]-acetic acid
- 25 11. (5-Fluoro-2-methyl-3-thiazol-2-ylmethyl-indol-1-yl)-acetic acid ethyl ester
12. [3-(4-Chloro-benzyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid
13. (3-Benzothiazol-2-ylmethyl-5-fluoro-2-methyl-indol-1-yl)-acetic acid
14. [5-Fluoro-2-methyl-3-(4-trifluoromethyl-benzyl)-indol-1-yl]-acetic acid
15. [5-Fluoro-2-methyl-3-(4-*tert*-butyl-benzyl)-indol-1-yl]-acetic acid
- 30 16. (3-Biphenyl-4-ylmethyl-5-fluoro-2-methyl-indol-1-yl)-acetic acid
17. [5-Fluoro-3-(4-methanesulfonyl-benzyl)-2-methyl-indol-1-yl]-acetic acid

18. [5-Fluoro-3-(6-fluoro-quinolin-2-ylmethyl)-2-methyl-indol-1-yl]-acetic acid
 19. (\pm)-3-(1-Benzothiazol-2-yl-ethyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid
 20. [3-(4,5,7-Trifluoro-benzothiazol-2-ylmethyl)-indol-1-yl]-acetic acid (lidorestat)
 21. (2-Methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid
 5 22. (5-Chloro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid;
 or the C₁-C₆ alkyl, aryl, (CH₂)_mOC(=O)C₁-C₆alkyl, (CH₂)_mN(R¹³)₂,
 CH((CH₂)_mO(C=O)R¹⁴)₂ esters of any of the above; wherein
 m is 1 or 2;
 R¹³ is hydrogen or methyl;
 10 R¹⁴ is C₁-C₁₈ alkyl.

Although some compounds of general formula (I) are known from the prior art,
 others represent a novel selection since they are not exemplified and the aromatic
 groups in the R⁸ position are not said to be preferred. Furthermore, these compounds
 15 have, surprisingly, been shown by the present inventors to have activity as
 antagonists of PGD₂ at the CRTH2 receptor.

Therefore, in a further aspect of the invention there is provided a compound of
 general formula (I) wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁹ are as defined above
 20 and R⁸ is a phenyl, naphthalenyl, thiazole, biphenyl, quinolinyl or quinoxaliny
 group, any of which may be substituted with one or more halo, C₁-C₆ alkyl, -O(C₁-
 C₆)alkyl, -SO₂R¹¹ or -OH groups;
 provided that.

- R⁸ is not unsubstituted phenyl or phenyl substituted with -COOH;
 25 when any two of R¹, R², R³ and R⁴ are hydrogen, neither of the other two of
 R¹, R², R³ and R⁴ is C₃-C₆ alkyl;
 when all of R¹, R², R³ and R⁴ are hydrogen, R⁸ is not 4-chlorophenyl.


In these novel compounds, preferred R⁸ groups are is phenyl substituted at the 4-
 30 position, naphthalen-2-yl, quinolin-2-yl, quinoxalin-2-yl or thiazol-2-yl and preferred
 substituents for these groups are chloro, fluoro, methyl, ethyl, t-butyl,

trifluoromethyl, methoxy, methanesulfonyl and hydroxy.

Preferred R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 and R^9 groups are as specified above.

- 5 Among the most preferred novel compounds are Compounds 1 to 19, 21 and 22 listed above and these compounds form a further aspect of the invention. Compound 20 was disclosed in WO-A-9950268.

The compound of general formula (I) may be derived *in vivo* from a prodrug. The
10 prodrug may be a compound of general formula (II):



II

- 15 wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 and R^9 are as defined for general formula (I); R^{12} is C_1 - C_6 alkyl, aryl, $(CH_2)_mOC(=O)C_1$ - C_6 alkyl, $(CH_2)_mN(R^{13})_2$, $CH((CH_2)_mO(C=O)R^{14})_2$;

m is 1 or 2;

R^{13} is hydrogen or methyl;

- 20 R^{14} is C_1 - C_{18} alkyl.

Therefore, in a further aspect of the invention there is provided the use of a compound of general formula (II) as defined above in the preparation of an agent for the treatment or prevention of diseases and conditions mediated by PGD_2 at the
25 CRTH2 receptor.

Examples of particularly suitable R^{12} groups when the compound of general formula

(II) is used as a prodrug include:

methyl, ethyl, propyl, phenyl, $\text{CH}_2\text{OC}(=\text{O})\text{tBu}$, $\text{CH}_2\text{CH}_2\text{N}(\text{Me})_2$, $\text{CH}_2\text{CH}_2\text{NH}_2$ or $\text{CH}(\text{CH}_2\text{O}(\text{C}=\text{O})\text{R}^{14})_2$ wherein R^{14} is as defined above.

- 5 Compounds of general formula (II) wherein R^8 is a phenyl, naphthalenyl, biphenyl, quinolyl or quinoxalyl group, any of which may be substituted with one or more halo, $\text{C}_1\text{-C}_6$ alkyl, $-\text{O}(\text{C}_1\text{-C}_6)\text{alkyl}$, $-\text{SO}_2\text{R}^{11}$ or $-\text{OH}$ groups; provided that.

- R^8 is not unsubstituted phenyl or phenyl substituted with $-\text{COOH}$;
 10 when any two of R^1 , R^2 , R^3 and R^4 are hydrogen, neither of the other two of R^1 , R^2 , R^3 and R^4 is $\text{C}_3\text{-C}_6$ alkyl;
 when all of R^1 , R^2 , R^3 and R^4 are hydrogen, R^8 is not 4-chlorophenyl;
 are new.


- 15 Some of the most preferred compounds of general formula (II) are the $\text{C}_1\text{-C}_6$ alkyl, aryl, $(\text{CH}_2)_m\text{OC}(=\text{O})\text{C}_1\text{-C}_6\text{alkyl}$, $(\text{CH}_2)_m\text{N}(\text{R}^{13})_2$, $\text{CH}((\text{CH}_2)_m\text{O}(\text{C}=\text{O})\text{R}^{14})_2$ esters of Compounds 1 to 19 above, wherein m , R^{13} and R^{14} are as defined above.

- When the compound of general formula (II) acts as a prodrug, it is later transformed
 20 to the drug by the action of an esterase in the blood or in a tissue of the patient.

- As is described in WO-A-9950268, compounds of general formula (I) may be prepared from compounds of general formula (II) in which R^{12} is $\text{C}_1\text{-C}_6$ alkyl by hydrolysis with an alkali such as sodium or lithium hydroxide. The reaction may
 25 take place in an aqueous solvent or an organic solvent or a mixture of the two. A typical solvent used for the reaction is a mixture of tetrahydrofuran and water

Compounds of general formula (II) may be prepared from compounds of general formula (III):

14



III

5 wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 and R^7 are as defined in general formula (I) and R^{12} is as defined in general formula (II); by reaction with a compound of general formula (IV):



10

wherein R^9 is as defined for general formula (I);
under acidic reductive alkylation conditions. Compounds of general formulae (III) and (IV) are readily available or can be prepared by methods well known to those skilled in the art.

15

Other methods of preparing compounds of general formulae (I) and (II) are set out in WO-A-9950268 and WO-A-0151489.

20

Compounds of general formula (I) are antagonists of PGD_2 at the CRTH2 receptor and compounds of general formula (II) are prodrugs for compounds of general formula (I). Compounds of general formulae (I) and (II) are therefore useful in a method for the treatment of diseases and conditions mediated by PGD_2 at the CRTH2 receptor, the method comprising administering to a patient in need of such treatment a suitable amount of a compound of general formula (I) or (II).

25

In a further aspect of the invention, there is provided a novel compound of general formula (I) or (II) for use in medicine, particularly for use in the treatment or

prevention of diseases and conditions mediated by PGD₂ at the CRTH2 receptor.

As mentioned above, such diseases and conditions include allergic asthma, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity
5 (including contact dermatitis), conjunctivitis, especially allergic conjunctivitis, eosinophilic bronchitis, food allergies, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis and Crohn's disease, mastocytosis and also other PGD₂-mediated diseases, for example autoimmune diseases such as hyper IgE syndrome and systemic lupus erythematus, psoriasis, acne, multiple sclerosis,
10 allograft rejection, reperfusion injury, chronic obstructive pulmonary disease, as well as rheumatoid arthritis, psoriatic arthritis and osteoarthritis.

The compounds of general formula (I) or (II) must be formulated in an appropriate manner depending upon the diseases or conditions they are required to treat.

15

Therefore, in a further aspect of the invention there is provided a pharmaceutical composition comprising a novel compound of general formula (I) or (II) together with a pharmaceutical excipient or carrier. Other active materials may also be present, as may be considered appropriate or advisable for the disease or condition
20 being treated or prevented.

The carrier, or, if more than one be present, each of the carriers, must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient.

25

The formulations include those suitable for oral, rectal, nasal, bronchial (inhaled), topical (including eye drops, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration and may be prepared by any methods well known in the art of pharmacy.

30

The route of administration will depend upon the condition to be treated but

preferred compositions are formulated for oral, nasal, bronchial or topical administration.

The composition may be prepared by bringing into association the above defined
5 active agent with the carrier. In general, the formulations are prepared by uniformly and intimately bringing into association the active agent with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product. The invention extends to methods for preparing a pharmaceutical composition comprising
10 bringing a novel compound of general formula (I) or (II) in conjunction or association with a pharmaceutically or veterinarily acceptable carrier or vehicle.

Formulations for oral administration in the present invention may be presented as: discrete units such as capsules, sachets or tablets each containing a predetermined amount of the active agent; as a powder or granules; as a solution or a suspension of
15 the active agent in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water in oil liquid emulsion; or as a bolus etc.

For compositions for oral administration (e.g. tablets and capsules), the term “acceptable carrier” includes vehicles such as common excipients e.g. binding
20 agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, polyvinylpyrrolidone (Povidone), methylcellulose, ethylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, sucrose and starch; fillers and carriers, for example corn starch, gelatin, lactose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride and alginic acid; and lubricants such as
25 magnesium stearate, sodium stearate and other metallic stearates, glycerol stearate stearic acid, silicone fluid, talc waxes, oils and colloidal silica. Flavouring agents such as peppermint, oil of wintergreen, cherry flavouring and the like can also be used. It may be desirable to add a colouring agent to make the dosage form readily identifiable. Tablets may also be coated by methods well known in the art.

30

A tablet may be made by compression or moulding, optionally with one or more

accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active agent in a free flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface-active or dispersing agent. Moulded tablets may be made by moulding in a
5 suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active agent.

Other formulations suitable for oral administration include lozenges comprising the
10 active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active agent in an inert base such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active agent in a suitable liquid carrier.

For topical application to the skin, compounds of general formula (I) or (II) may be
15 made up into a cream, ointment, jelly, solution or suspension etc. Cream or ointment formulations that may be used for the drug are conventional formulations well known in the art, for example, as described in standard text books of pharmaceutics such as the British Pharmacopoeia.

20 Compounds of general formula (I) or (II) may be used for the treatment of the respiratory tract by nasal, bronchial or buccal administration of, for example, aerosols or sprays which can disperse the pharmacological active ingredient in the form of a powder or in the form of drops of a solution or suspension. Pharmaceutical compositions with powder-dispersing properties usually contain, in addition to the
25 active ingredient, a liquid propellant with a boiling point below room temperature and, if desired, adjuncts, such as liquid or solid non-ionic or anionic surfactants and/or diluents. Pharmaceutical compositions in which the pharmacological active ingredient is in solution contain, in addition to this, a suitable propellant, and furthermore, if necessary, an additional solvent and/or a stabiliser. Instead of the
30 propellant, compressed air can also be used, it being possible for this to be produced as required by means of a suitable compression and expansion device.

Parenteral formulations will generally be sterile.

Typically, the dose of the compound will be about 0.01 to 100 mg/kg; so as to
5 maintain the concentration of drug in the plasma at a concentration effective to
inhibit PGD₂ at the CRTH2 receptor. The precise amount of a compound of general
formula (I) or (II) which is therapeutically effective, and the route by which such
compound is best administered, is readily determined by one of ordinary skill in the
art by comparing the blood level of the agent to the concentration required to have a
10 therapeutic effect.

Compounds of general formula (I) or (II) may be used in combination with one or
more active agents which are useful in the treatment of the diseases and conditions
listed above, although these active agents are not necessarily inhibitors of PGD₂ at
15 the CRTH2 receptor.

Therefore, the pharmaceutical composition described above may additionally contain
one or more of these active agents.

20 There is also provided the use of a compound of general formula (I) or (II) in the
preparation of an agent for the treatment of diseases and conditions mediated by
PGD₂ at the CRTH2 receptor, wherein the agent also comprises an additional active
agent useful for the treatment of the same diseases and conditions.

25 These additional active agents which may have a completely different mode of action
include existing therapies for allergic and other inflammatory diseases including:
β₂ agonists such as salmeterol;
corticosteroids such as fluticasone;
antihistamines such as loratidine;
30 leukotriene antagonists such as montelukast;
anti-IgE antibody therapies such as omalizumab;

anti-infectives such as fusidic acid (particularly for the treatment of atopic dermatitis);

anti-fungals such as clotrimazole (particularly for the treatment of atopic dermatitis);

immunosuppressants such as tacrolimus and particularly pimecrolimus in the case of

5 inflammatory skin disease.

CRTH2 antagonists may also be combined with therapies that are in development for inflammatory indications including:

other antagonists of PGD₂ acting at other receptors, such as DP antagonists;

10 inhibitors of phosphodiesterase type 4 such as cilionilast;

drugs that modulate cytokine production such as inhibitors of TNF α converting enzyme (TACE);

drugs that modulate the activity of Th2 cytokines IL-4 and IL-5 such as blocking monoclonal antibodies and soluble receptors;

15 PPAR- γ agonists such as rosiglitazone;

5-lipoxygenase inhibitors such as zileuton.

In yet a further aspect of the invention, there is provided a product comprising a novel compound of general formula (I) or (II) and one or more of the agents listed
20 above as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease or condition mediated by the action of PGD₂ at the CRTH2 receptor.

The invention will now be described in greater detail with reference to the following
25 non limiting examples.

Example 1 – Preparation of Compounds 1 to 19

1. {3-[1-(4-Chloro-phenyl)-ethyl]-5-fluoro-2-methyl-indol-1-yl}-acetic acid
30 ethyl ester

Triethylsilane (0.34 ml, 2.13 mmol) and trifluoroacetic acid (0.10 ml, 1.29 mmol)

were sequentially added dropwise over 1 min to a stirred solution of (5-fluoro-2-methyl-indol-1-yl)-acetic acid ethyl ester (0.10 g, 0.43 mmol) and 4-acetylchlorobenzene (64 mg, 0.41 mmol) in 1,2-dichloroethane (2 ml) at 0 °C. The mixture was then warmed to room temperature and stirred for 16 h. The resulting mixture was concentrated *in vacuo* to leave a residue which was partitioned between ethyl acetate (10 ml) and a saturated solution of sodium bicarbonate (10 ml). The organic layer was separated, dried, and concentrated *in vacuo* to leave a residue which was purified by flash column chromatography (Flashmaster) on silica gel eluting with 10 % ethyl acetate : heptane to 25 % ethyl acetate : heptane to give the ethyl ester (57 mg, 37 %) as a white solid, Tr = 1.88 min (92 %), *m/z* (ES⁺) (M+H)⁺ 374.30.

2. Compound 1 – {3-[1-(4-Chloro-phenyl)-ethyl]-5-fluoro-2-methyl-indol-1-yl}-acetic acid

Lithium hydroxide monohydrate (70 mg, 1.67 mmol) was added in one portion to a stirred solution of {3-[1-(4-chloro-phenyl)-ethyl]-5-fluoro-2-methyl-indol-1-yl}-acetic acid ethyl ester (57 mg, 0.15 mmol) in tetrahydrofuran : water (5 ml; 1:1) and stirred at room temperature for 2 h. The solution was adjusted to pH 1 with concentrated hydrochloric acid and the product extracted with ethyl acetate (3 x 10 ml). The combined organic extracts were dried and concentrated *in vacuo* to give the carboxylic acid (35 mg, 67 %) as an off-white solid, δ_H (400 MHz, CDCl₃) 7.26-7.21 (4H, m, Ar), 7.06 (1H, dd *J* 9.0, 4.2 Hz, Ar), 6.97 (1H, dd *J* 10.0, 2.4 Hz, Ar), 6.86 (1H, dt *J* 9.0, 2.4 Hz, Ar), 4.80 (2H, s, CH₂CO₂H), 4.35 (1H, q *J* 7.3 Hz, CHCH₃), 2.29 (3H, s, CH₃), 1.73 (3H, d *J* 7.3 Hz, CHCH₃); Tr = 1.73 min (90 %), *m/z* (ES⁺) (M+H)⁺ 346.09.

Compounds 2 to 19, 21 and 22 were prepared using a similar method to that described for Compound 1, but with appropriately chosen starting materials.

Compound 2 – {5-Fluoro-2-methyl-3-[1-(4-trifluoromethyl-phenyl)-ethyl]-indol-1-yl}-acetic acid

δ_{H} (400 MHz, CDCl_3) 7.50 (2H, d J 8.3 Hz, *Ar*), 7.39 (2H, d J 8.3 Hz, *Ar*), 7.07 (1H, dd J 8.8, 4.1 Hz, *Ar*), 6.98 (1H, dd J 10.0, 2.5 Hz, *Ar*), 6.85 (1H, dt J 9.0, 2.5 Hz, *Ar*), 4.80 (2H, s, $\text{CH}_2\text{CO}_2\text{H}$), 4.42 (1H, q J 7.1 Hz, CHCH_3), 2.29 (3H, s, CH_3), 1.77 (3H, d J 7.3 Hz, CHCH_3); Tr = 1.65 min (96%), m/z (ES^+) ($\text{M}+\text{H}$)⁺ 380.15.

Compound 3 – {3-[1-(4-*tert*-Butyl-phenyl)-ethyl]-5-fluoro-2-methyl-indol-1-yl}-acetic acid

δ_{H} (400 MHz, CDCl_3) 7.32-7.21 (4H, m, *Ar*), 7.08-7.03 (2H, m, *Ar*), 6.89-6.83 (1H, m, *Ar*), 4.82 (2H, s, $\text{CH}_2\text{CO}_2\text{H}$), 4.36 (1H, q J 7.3 Hz, CHCH_3), 2.33 (3H, s, CH_3), 1.75 (3H, d J 7.3 Hz, CHCH_3), 1.29 (9H, s, $\text{C}(\text{CH}_3)_3$); Tr = 1.78 min (97%), m/z (ES^+) ($\text{M}+\text{H}$)⁺ 368.21.

Compound 4 – {5-Fluoro-3-[1-(4-methanesulfonyl-phenyl)-ethyl]-2-methyl-indol-1-yl}-acetic acid

δ_{H} (400 MHz, CDCl_3) 7.81 (2H, d J 8.3 Hz, *Ar*), 7.47 (2H, d J 8.1 Hz, *Ar*), 7.06 (1H, dd J 8.8, 4.1 Hz, *Ar*), 6.96 (1H, dd J 10.0, 2.5 Hz, *Ar*), 6.85 (1H, dt J 9.0, 2.5 Hz, *Ar*), 4.78 (2H, s, $\text{CH}_2\text{CO}_2\text{H}$), 4.43 (1H, q J 7.1 Hz, CHCH_3), 2.99 (3H, s, CH_3), 2.29 (3H, s, CH_3), 1.79 (3H, d J 7.3 Hz, CHCH_3); Tr = 1.34 min (100%), m/z (ES^+) ($\text{M}+\text{H}$)⁺ 390.16.

Compound 5 – [5-Fluoro-2-methyl-3-(1-naphthalen-2-yl-ethyl)-indol-1-yl]-acetic acid

δ_{H} (400 MHz, CDCl_3) 7.81-7.74 (3H, m, *Ar*), 7.69 (1H, d J 8.5 Hz, *Ar*), 7.47-7.39 (2H, m, *Ar*), 7.39-7.33 (1H, m, *Ar*), 7.09-7.02 (2H, m, *Ar*), 6.86 (1H, dt J 9.0, 2.4 Hz, *Ar*), 4.83 (2H, s, $\text{CH}_2\text{CO}_2\text{H}$), 4.54 (1H, q J 7.3 Hz, CHCH_3), 2.32 (3H, s, CH_3), 1.86 (3H, d J 7.3 Hz, CHCH_3); Tr = 1.66 min (97%), m/z (ES^+) ($\text{M}+\text{H}$)⁺ 362.19.

Compound 6 – (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid

δ_{H} (400 MHz, d_6 -DMSO) 8.42 (1H, d J 9.0 Hz, *Ar*), 8.23 (1H, d J 9.0 Hz, *Ar*), 8.11

(1H, m, Ar), 7.97 (1H, m, Ar), 7.60 (1H, m, Ar) 7.51 (3H, m, Ar and Ar), 7.09 (1H, m, Ar), 5.19 (2H, s, CH₂), 4.56 (2H, CH₂), 2.63 (3H, s, CH₃); Tr = 1.06 min (100 %), *m/z* (ES⁺) (M+H)⁺ 349.35.

5 **Compound 7 – (5-Fluoro-2-methyl-3-naphthalen-2-ylmethyl-indol-1-yl)-acetic acid**

δ_H (400 MHz, *d*₆-DMSO) 7.87 (4H, m, Ar), 7.47 (4H, m, Ar), 7.22 (1H, dd *J* 6.0, 1.5 Hz, Ar), 6.91 (1H, ddd *J* 9.0, 2.5 Hz, Ar), 5.04 (2H, s, CH₂), 4.23 (2H, s, CH₂), 2.42 (3H, s, CH₃); Tr = 2.09 min, *m/z* (ES⁺) (M+H)⁺ 348.13.

10

Compound 8 – [5-Fluoro-3-(8-hydroxy-quinolin-2-ylmethyl)-2-methyl-indol-1-yl]-acetic acid

δ_H (400 MHz, *d*₆-DMSO) 9.53 (1H, s, OH), 8.20 (1H, d *J* 8.0 Hz, Ar), 7.42 (5H, m, Ar), 7.13 (1H, dd *J* 6.0, 1.5 Hz, Ar), 6.91 (1H, dd *J* 9.0, 2.5 Hz, Ar), 5.00 (2H, s, CH₂), 4.41 (2H, s, CH₂), 2.47 (3H, s, CH₃); Tr = 1.13 min, *m/z* (ES⁺) (M+H)⁺ 365.12.

15

Compound 9 – (5-Fluoro-2-methyl-3-quinoxalin-2-ylmethyl-indol-1-yl)-acetic acid

δ_H (400 MHz, *d*₆-DMSO) 9.02 (1H, s, H-3 Ar), 8.30 (2H, m, Ar), 8.05 (2H, m, Ar), 7.53 (2H, m, Ar), 7.07 (1H, m, Ar), 5.01 (2H, br s, CH₂), 4.64 (2H, s, CH₂), 2.64 (3H, s, CH₃); Tr = 1.35 min, *m/z* (ES⁺) (M+H)⁺ 350.12.

20

Compound 10 – [5-Fluoro-3-(4-methoxy-benzyl)-2-methyl-indol-1-yl]-acetic acid

δ_H (400 MHz, *d*₆-DMSO) 7.39 (1H, m, Ar), 7.16 (3H, m, Ar), 6.91 (3H, m, Ar) 5.00 (2H, s, CH₂), 3.98 (2H, s, CH₂), 3.74 (3H, s, OCH₃) 2.36 (3H, s, CH₃); Tr = 1.93 min, *m/z* (ES⁺) (M+H)⁺ 328.13.

25

Compound 11 – (5-Fluoro-2-methyl-3-thiazol-2-ylmethyl-indol-1-yl)-acetic acid ethyl ester

30

Tr = 1.09 min, *m/z* (ES⁺) (M+H)⁺ 305.26.

Compound 12 – [3-(4-Chloro-benzyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid

Tr = 1.63 min (100 %), m/z (ES^+) ($M+H$)⁺ 332.16.

Compound 13 – (3-Benzothiazol-2-ylmethyl-5-fluoro-2-methyl-indol-1-yl)-acetic acid

Tr = 1.43 min, m/z (ES^+) ($M+H$)⁺ 355.17.

Compound 14 – [5-Fluoro-2-methyl-3-(4-trifluoromethyl-benzyl)-indol-1-yl]-acetic acid

Tr = 1.66 min, m/z (ES^+) ($M+H$)⁺ 366.06.

Compound 15 – [5-Fluoro-2-methyl-3-(4-*tert*-butyl-benzyl)-indol-1-yl]-acetic acid

Tr = 1.73 min, m/z (ES^+) ($M+H$)⁺ 354.21.

Compound 16 – (3-Biphenyl-4-ylmethyl-5-fluoro-2-methyl-indol-1-yl)-acetic acid

Tr = 2.10 min, m/z (ES^+) ($M+H$)⁺ 374.16.

Compound 17 – [5-Fluoro-3-(4-methanesulfonyl-benzyl)-2-methyl-indol-1-yl]-acetic acid

Tr = 1.35 min, m/z (ES^+) = 376.05.

Compound 18 – [5-Fluoro-3-(6-fluoro-quinolin-2-ylmethyl)-2-methyl-indol-1-yl]-acetic acid

δ_H (400 MHz, d_6 -DMSO) 8.20 (1H, d J 8.6 Hz, *Ar*), 8.06 (1H, dd J 9.3, 5.6 Hz, *Ar*), 7.70 (1H, dd J 9.4, 2.8 Hz, *Ar*), 7.64 (1H, td J 8.8, 2.9 Hz, *Ar*), 7.37-7.32 (2H, m, *Ar*), 7.26 (1H, dd J 9.9, 2.6 Hz, *Ar*), 6.86 (1H, td J 9.2, 2.4 Hz, *Ar*), 4.94 (2H, s, CH_2), 4.33 (2H, s, CH_2), 2.40 (3H, s, CCH_3); Tr = 1.28 min (100 %), m/z (ES^+) ($M+H$)⁺ 367.50.

Compound 19 – (±)-3-(1-Benzothiazol-2-yl-ethyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid

δ_H (400 MHz, d_6 -DMSO) 8.01 (1H, d J 7.7 Hz, Ar), 7.95 (1H, d J 8.0 Hz, Ar), 7.49 (1H, obs t J 7.2 Hz, Ar), 7.43-7.36 (2H, m, Ar), 7.10 (1H, dd J 10.1, 2.5 Hz, Ar), 6.89 (1H, td J 9.2, 2.4 Hz, Ar), 5.01 (2H, s, CH_2), 4.91 (1H, q, J 7.1 Hz, $CHCH_3$), 2.37 (3H, s, CCH_3), 1.87 (3H, d J 7.1 Hz, $CHCH_3$); Tr = 1.53 min, m/z (ES^+) ($M+H$)⁺ 369.10.

Compound 21 – (2-Methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid

δ_H (400 MHz, d_6 -DMSO) 8.16 (1H, d J 8.6 Hz, Ar), 8.01 (1H, d J 8.5 Hz, Ar), 7.88 (1H, d J 7.6 Hz, Ar), 7.74 (1H, t J 7.0 Hz, Ar), 7.54 (1H, t J 7.0 Hz, Ar), 7.44 (1H, d J 8.0 Hz, Ar), 7.26 (2H, app t J 8.9 Hz, Ar), 7.00 (1H, t J 7.3 Hz, Ar), 6.90 (1H, t J 7.3 Hz, Ar), 4.72 (2H, s, CH_2CO_2H), 4.35 (2H, s, CH_2), 2.40 (3H, s, CH_3); Tr = 1.07 min (100 %), m/z (ES^+) ($M+H$)⁺ 331.33.

Compound 22 – (5-Chloro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid

δ_H (400 MHz, d_6 -DMSO) 8.21 (1H, d J 8.4 Hz, Ar), 8.00 (1H, d J 8.4 Hz, Ar), 7.89 (1H, d J 8.0 Hz, Ar), 7.77-7.73 (1H, m, Ar), 7.57-7.53 (2H, m, Ar), 7.40 (1H, d J 8.7 Hz, Ar), 7.29 (1H, d J 8.5 Hz, Ar), 7.04 (1H, dd J 8.6, 2.1 Hz, Ar), 5.00 (2H, s, CH_2CO_2H), 4.35 (2H, s, CH_2), 2.41 (3H, s, CH_3); Tr = 1.17 min (95 %), m/z (ES^+) ($M+H$)⁺ 365.28.

Example 2 – Preparation of Compound 20

1. [3-(4,5,7-Trifluoro-benzothiazol-2-ylmethyl)-indol-1-yl]-acetic acid ethyl ester

This compound was prepared using the procedure set out in WO-A-0151489.

δ_H (400 MHz, d_6 -DMSO) 7.75-7.69 (1H, m, Ar), 7.56 (1H, d J 7.8 Hz, Ar), 7.49 (1H, s, CH), 7.43 (1H, d J 8.2 Hz, Ar), 7.19 (1H, app t J 7.0 Hz, Ar), 7.08 (1H, app t J 7.1 Hz, Ar), 5.17 (2H, s, CH_2), 4.69 (2H, s, CH_2); 4.17 (2H, q J 7.2 Hz, CH_2CH_3), 1.23

(3H, t J 7.2 Hz, CH_2CH_3); Tr = 1.62 min, m/z (ES^+) ($\text{M}+\text{H}$)⁺ 405.15.

2. Compound 20 – [3-(4,5,7-Trifluoro-benzothiazol-2-ylmethyl)-indol-1-yl]-acetic acid

5 Lithium hydroxide (31 mg, 0.74 mmol) in water (6 ml) was added in one portion to a stirred solution of [3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-indol-1-yl]-acetic acid ethyl ester (73 mg, 0.18 mmol) in tetrahydrofuran (6 ml) at room temperature. The mixture was stirred at room temperature for 15 min and then the solution was adjusted to pH ~3 with 1M hydrochloric acid. The aqueous layer was then extracted
10 with ethyl acetate (3 x 10 ml) and the combined organic extracts were washed with brine (10 ml), dried and concentrated *in vacuo* to give the *carboxylic acid* (62 mg, 92 %) as a yellow solid, δ_{H} (400 MHz, d_6 -DMSO) 7.76-7.69 (1H, m, Ar), 7.56 (1H, d J 8.0 Hz, Ar), 7.48 (1H, s, CH), 7.43 (1H, d J 8.3 Hz, Ar), 7.18 (1H, app t J 7.1 Hz, Ar), 7.07 (1H, app t J 7.1 Hz, Ar), 5.05 (2H, s, CH_2), 4.68 (2H, s, CH_2); Tr = 1.94
15 min, m/z (ES^+) ($\text{M}+\text{H}$)⁺ 377.00.

Example 3 – Measurement of CRTH2 Antagonist Activity

Materials and Methods

20

Materials

Calcium-3 dye was purchased from Molecular Devices (Wokingham, UK). Mono-poly resolving medium was obtained from Dainippon Pharmaceuticals (Osaka, Japan). Macs anti-CD16 microbeads were from Miltenyi biotec (Bisley, Surrey).
25 ChemoTx plates were purchased from Neuroprobe (Gaithersburg, MD). Poly-D-lysine coated 96-well plates were obtained from Greiner (Gloucestershire, UK). [³H]PGD₂ was from Amersham Biosciences (Buckinghamshire, UK). [³H]SQ29548 was purchased from Perkin Elmer Life Sciences (Buckinghamshire, UK). All other reagents were obtained from Sigma-Aldrich (Dorset, UK), unless otherwise stated.

Methods

Cell culture

Chinese Hamster Ovary cells were transfected with CRTH2 or DP receptors (CHO/CRTH2 and CHO/DP) and were maintained in culture in a humidified atmosphere at 37°C (5% CO₂) in Minimum Essential Medium (MEM) supplemented with 10% foetal bovine serum, 2 mM glutamine, and 1 mg ml⁻¹ active G418. The cells were passaged every 2-3 days. For radioligand binding assay, cells were prepared in triple-layer flasks or in 175 cm² square flasks (for membrane preparation). For calcium mobilisation assay, cells were grown in a 96 well plate 24h prior to the assay at a density of 80,000 cells per well.

Preparation of cell membranes

Membranes were prepared either from CHO/CRTH2 and CHO/DP cells, or from platelets (as a source of TP receptors). CHO cells grown to confluency were washed with PBS and detached using a Versene solution (15 ml per flask). When the cells were grown in 175 cm² square flask, they were collected by scrapping in PBS. The cell suspensions were centrifuged (1,700 rpm, 10 min, 4°C) and resuspended in 15 ml of buffer (1xHBSS, supplemented with 10 mM HEPES, pH 7.3). Cell suspensions were then homogenised using an Ultra Turrax at setting 4-6 for 20 s. The homogenate was centrifuged at 1,700 rpm for 10 min and the supernatant was collected and centrifuged at 20,000 rpm for 1h at 4°C. The resulting pellet was resuspended in buffer and stored at -80°C in aliquots of 200-500 µl. The protein concentration was determined by the method of Bradford (1976), using bovine serum albumin as standard. The platelets were washed by centrifugation at 600xg for 10 min and resuspended in ice-cold assay buffer (10 mM Tris-HCl, pH 7.4, 5 mM Glucose, 120 mM NaCl, 10 µM indomethacin) and directly centrifuged at 20,000 rpm for 30 min at 4°C. The resulting pellet was treated as described above.

Radioligand binding assays

[³H]PGD₂ (160 Ci/mmol) binding experiments were performed on membranes prepared as described above. Assays were performed in a final volume of 100 µl of

buffer (1XHBSS/HEPES 10 mM, pH 7.3). Cell membranes (15µg). Cell membranes 15mg were preincubated at room temperature with varying concentration of competing ligand for 15 min. [³H]PGD₂ (mol, final concentration) was then added and the incubation continued for a further one hour at room temperature. The reaction was terminated by the addition of 200 µl ice-cold assay buffer to each well, followed by rapid filtration through Whatman GF/B glass fibre filters using a Unifilter Cell harvester (PerkinElmer Life Sciences) and six washes of 300 µl of ice-cold buffer. The Unifilter plates were dried at room temperature for at least 1h and the radioactivity retained on the filters was determined on a Beta Trilux counter (PerkinElmer Life Sciences), following addition of 40 µl of Optiphase Hi-Safe 3 (Wallac) liquid scintillation. Non specific binding was defined in the presence of 10 µM unlabelled PGD₂. Assays were performed in duplicate.

The results of the radioligand binding experiments to the CRTH2 and DP receptors are shown in Tables 1 and 2.

Table 1 – Radioligand binding data (Ki on CRTH2 Receptor).

Compounds	Ki (nM)
Compound 4	5±4
Compound 6	9±3
Compound 8	6±4
Compound 12	11±2
Compound 13	6±1
Compound 17	7±2
Compound 18	1.3±0.6
Compound 20 (lidorestat)	886±248

Table 2 – Radioligand binding data (Ki on DP Receptor).

Compounds	Ki (nM)
Compound 4	30440±9805
Compound 6	17870±7290
Compound 8	7710±1780
Compound 12	12220±2250
Compound 18	7740±1442
Compound 20 (lidorestat)	3960

The TP receptor radioligand binding was done on membranes prepared from platelets. 15-40 μg of protein were pre-incubated with varying concentrations of competing ligand for 15 min at room temperature in assay buffer (10 mM Tris-HCl, pH 7.4, 5 mM glucose, 120 mM NaCl, 10 μM indomethacin). [^3H]SQ29548 (38 Ci/mmol, 10 nM final concentration) was then added and the incubation continued for a further 30 min at room temperature. The reaction was terminated by the addition of 200 μl ice-cold assay buffer to each well, followed by rapid filtration through Whatman GF/C glass fibre filters using a Unifilter Cell harvester (PerkinElmer Life Sciences) followed with six washes of 300 μl of ice-cold buffer. The radioactivity was determined as described above.

All of the compounds studied in this assay bound to the TP receptor with low affinity ($K_i > 1\mu\text{M}$).

Compounds of general formula (I) bound to CRTH2 receptor expressed in CHO cells with a range of affinity varying from very high to moderate. In fact the K_i values determined in competition versus [^3H]PGD₂ varied from 500 pM to 1 μM . Compounds of general formula (I) had no activity (or very weak activity) at the DP and TP receptors. The binding selectivity of the compounds of general formula (I) for CRTH2 receptor was greater than 200 fold for CRTH2 receptor, compared to DP and TP receptors.

Calcium mobilisation Assay

Cells were seeded onto poly-D-lysine coated 96-well plates at a density of 80,000 cells per well and incubated at 37°C overnight to allow the cells to adhere. Cells were washed twice with HBSS and incubated for 1h at 37°C in 100 μl HBSS and 100 μl calcium-3-dye (Molecular Devices), supplemented with 4mM probenecid. Changes in fluorescence were monitored over a 50s time course with agonist addition at 17s using a Flexstation (Molecular Devices).

Effect of CRTH2 agonists on calcium mobilisation in CHO-CRTH2 cells

PGD₂ caused a dose-dependent increase in intracellular Ca^{2+} mobilisation in CHO/CRTH2 cells, with an $\text{EC}_{50} = 2.4 \pm 0.5\text{nM}$ (n=3).

Effect of compounds of general formula (I) on the calcium mobilisation induced by PGD₂

PGD₂-stimulated Ca²⁺ flux was fully inhibited by the compounds of general formula (I) and the IC₅₀ value for each compound in the calcium assay was comparable to its
 5 Ki value in Radioligand binding. IC₅₀ values of compounds of general formula (I) varied from 5 nM to 1 µM. The results for several compounds of general formula (I) are shown in Table 3. Increasing doses of the compounds of general formula (I) caused a dose-dependent and parallel shift of the PGD₂ dose response curve in CHO/CRTH2 cells, thereby indicating that the compounds are competitive CRTH2
 10 antagonists.


The antagonistic effect of the compounds of general formula (I) appears to be CRTH2 selective, since no inhibitory effect was seen with ATP-stimulated Ca²⁺ flux.

15 **Table 3 – Inhibition of PGD₂-induced calcium flux**

Compounds	IC ₅₀ (nM)
Compound 4	55±18
Compound 6	30±6
Compound 7	38±16
Compound 8	11±6
Compound 10	47±8
Compound 12	108±29
Compound 17	64±5
Compound 18	10±5
Compound 19	34±7
Compound 20 (lidorestat)	885±96

CLAIMS

1. The use of a compound of general formula (I):



I

wherein

- 10 R^1 , R^2 , R^3 and R^4 are independently hydrogen, halo, C_1 - C_6 alkyl, $-O(C_1$ - C_6 alkyl), $-CON(R^{11})_2$, $-SOR^{11}$, $-SO_2R^{11}$, $-SO_2N(R^{11})_2$, $-N(R^{11})_2$, $-NR^{11}COR^{11}$, $-CO_2R^{11}$, $-COR^{11}$, $-SR^{11}$, $-OH$, $-NO_2$ or $-CN$;

each R^{11} is independently hydrogen or C_1 - C_6 alkyl;

R^5 and R^6 are each independently hydrogen, or C_1 - C_6 alkyl or together with the carbon atom to which they are attached form a C_3 - C_7 cycloalkyl group;

- 15 R^7 is hydrogen or C_1 - C_6 alkyl;

R^8 is an aromatic moiety optionally substituted with one or more substituents selected from halo, C_1 - C_6 alkyl, $-O(C_1$ - C_6)alkyl, $-CON(R^{11})_2$, $-SOR^{11}$, $-SO_2R^{11}$, $-SO_2N(R^{11})_2$, $-N(R^{11})_2$, $-NR^{11}COR^{11}$, $-CO_2R^{11}$, $-COR^{11}$, $-SR^{11}$, $-OH$, $-NO_2$ or $-CN$;

wherein R^{11} is as defined above;

- 20 R^9 is hydrogen, or C_1 - C_6 alkyl;

provided that:


R^8 is not phenyl substituted with $-COOH$;

when any two of R^1 , R^2 , R^3 and R^4 are hydrogen, neither of the other two of R^1 , R^2 , R^3 and R^4 is C_3 - C_6 alkyl;

- 25 or a pharmaceutically acceptable salt, hydrate, solvate, complex or prodrug thereof;
in the preparation of an agent for the treatment or prevention of allergic asthma, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact

hypersensitivity (including contact dermatitis), conjunctivitis, especially allergic conjunctivitis, eosinophilic bronchitis, food allergies, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis and Crohn's disease, mastocytosis and also other PGD₂-mediated diseases, for example autoimmune diseases such as hyper IgE syndrome and systemic lupus erythematus, psoriasis, acne, multiple sclerosis, allograft rejection, reperfusion injury, chronic obstructive pulmonary disease, rheumatoid arthritis, psoriatic arthritis and osteoarthritis.

2. The use of a compound of general formula (II)



II

wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ are as defined in claim 1; R¹² is C₁-C₆ alkyl, aryl, (CH₂)_mOC(=O)C₁-C₆alkyl, (CH₂)_mN(R¹³)₂, CH((CH₂)_mO(C=O)R¹⁴)₂;

m is 1 or 2;

R¹³ is hydrogen or methyl;

R¹⁴ is C₁-C₁₈ alkyl;

in the preparation of an agent for the treatment or prevention of allergic asthma, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity (including contact dermatitis), conjunctivitis, especially allergic conjunctivitis, eosinophilic bronchitis, food allergies, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis and Crohn's disease, mastocytosis and also other PGD₂-mediated diseases, for example autoimmune diseases such as hyper IgE syndrome and systemic lupus erythematus, psoriasis, acne, multiple sclerosis, allograft rejection, reperfusion injury, chronic obstructive pulmonary disease, rheumatoid arthritis, psoriatic arthritis and osteoarthritis.

3. The use as claimed in claim 1 or claim 2 wherein, in the compound of general formula (I) or (II), independently or in any combination:
R¹ is halo or hydrogen;
R² is halo or hydrogen;
5 R³ is halo or hydrogen;
R⁴ is halo or hydrogen;
R⁵ and R⁶ are each independently hydrogen or C₁-C₄ alkyl;
R⁷ is H or C₁-C₆ alkyl; and
R⁹ is hydrogen or C₁-C₄ alkyl.
- 10 4. The use as claimed in claim 3 wherein, in the compound of general formula (I) or (II), R¹, R³ and R⁴ are hydrogen, while R² is halo.
- 15 5. The use as claimed in claim 4 wherein, in the compound of general formula (I) or (II), R² is fluoro.
6. The use as claimed in any one of claims 3 to 5, wherein in the compound of general formula (I) or (II), least one of R⁵ and R⁶ is hydrogen.
- 20 7. The use as claimed in any one of claims 3 to 6 wherein, in the compound of general formula (I) or (II), R⁷ is methyl.
8. The use as claimed in any one of claims 1 to 7, wherein, in the compound of general formula (I) or (II), R⁸ is phenyl, naphthalenyl, quinolinyl, quinoxalinyl,
25 thiazolyl, biphenyl or benzothiazolyl, any of which is optionally substituted by a substituent as defined in claim 1.
9. The use as claimed in claim 8, wherein the R⁸ moiety is phenyl substituted at the 4-position or naphthalen-2-yl, quinolin-2-yl, quinoxalin-2-yl, thiazol-2-yl or
30 benzothiazol-2-yl, any of which is optionally substituted with one or more of the substituents defined in claim 1.

10. The use as claimed in claim 8 or claim 9 wherein the R⁸ moiety is substituted with one or more substituents selected from halo, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₁-C₄ alkylsulfonyl and hydroxy.

5

11. The use as claimed in claim 10, wherein the R⁸ moiety is substituted with one or more substituents chosen from chloro, fluoro, methyl, ethyl, t-butyl, trifluoromethyl, methoxy, methanesulfonyl and hydroxy.

10 12. The use as claimed in any one of claims 1 to 11 wherein the compound of general formula (I) or (II) is:

{3-[1-(4-Chloro-phenyl)-ethyl]-5-fluoro-2-methyl-indol-1-yl}-acetic acid

{5-Fluoro-2-methyl-3-[1-(4-trifluoromethyl-phenyl)-ethyl]-indol-1-yl}-acetic acid

{3-[1-(4-*tert*-Butyl-phenyl)-ethyl]-5-fluoro-2-methyl-indol-1-yl}-acetic acid

15 {5-Fluoro-3-[1-(4-methanesulfonyl-phenyl)-ethyl]-2-methyl-indol-1-yl}-acetic acid

[5-Fluoro-2-methyl-3-(1-naphthalen-2-yl-ethyl)-indol-1-yl]-acetic acid

(5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid

(5-Fluoro-2-methyl-3-naphthalen-2-ylmethyl-indol-1-yl)-acetic acid

[5-Fluoro-3-(8-hydroxy-quinolin-2-ylmethyl)-2-methyl-indol-1-yl]-acetic acid

20 (5-Fluoro-2-methyl-3-quinoxalin-2-ylmethyl-indol-1-yl)-acetic acid

[5-Fluoro-3-(4-methoxy-benzyl)-2-methyl-indol-1-yl]-acetic acid

(5-Fluoro-2-methyl-3-thiazol-2-ylmethyl-indol-1-yl)-acetic acid ethyl ester

[3-(4-Chloro-benzyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid

(3-Benzothiazol-2-ylmethyl-5-fluoro-2-methyl-indol-1-yl)-acetic acid

25 [5-Fluoro-2-methyl-3-(4-trifluoromethyl-benzyl)-indol-1-yl]-acetic acid

[5-Fluoro-2-methyl-3-(4-*tert*-butyl-benzyl)-indol-1-yl]-acetic acid

(3-Biphenyl-4-ylmethyl-5-fluoro-2-methyl-indol-1-yl)-acetic acid

[5-Fluoro-3-(4-methanesulfonyl-benzyl)-2-methyl-indol-1-yl]-acetic acid

[5-Fluoro-3-(6-fluoro-quinolin-2-ylmethyl)-2-methyl-indol-1-yl]-acetic acid

30 (±)-3-(1-Benzothiazol-2-yl-ethyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid

[3-(4,5,7-Trifluoro-benzothiazol-2-ylmethyl)-indol-1-yl]-acetic acid (lidorestat)

(2-Methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid

(5-Chloro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid;

or the C₁-C₆ alkyl, aryl, (CH₂)_mOC(=O)C₁-C₆alkyl, (CH₂)_mN(R¹³)₂, CH((CH₂)_mO(C=O)R¹⁴)₂ esters of any of the above; wherein

5 m is 1 or 2;

R¹³ is hydrogen or methyl;

R¹⁴ is C₁-C₁₈ alkyl.

13. A compound of general formula (I) as defined in claim 1 or general formula
 10 (II) as defined in claim 2 wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁹ are as defined in claim 1, R¹² is as defined in claim 2 and R⁸ is a phenyl, naphthalenyl, thiazole, biphenyl, quinolinyl or quinoxalinyl group, any of which may be substituted with one or more halo, C₁-C₆ alkyl, -O(C₁-C₆)alkyl, -SO₂R¹¹ or -OH groups; provided that.

15 R⁸ is not unsubstituted phenyl or phenyl substituted with -COOH;
 when any two of R¹, R², R³ and R⁴ are hydrogen, neither of the other two of R¹, R², R³ and R⁴ is C₃-C₆ alkyl;
 when all of R¹, R², R³ and R⁴ are hydrogen, R⁸ is not 4-chlorophenyl.

20

14. A compound as claimed in claim 13, wherein, independently or in any combination:

R¹ is halo or hydrogen;

R² is halo or hydrogen;

25 R³ is halo or hydrogen;

R⁴ is halo or hydrogen;

R⁵ and R⁶ are each independently hydrogen or C₁-C₄ alkyl;

R⁷ is H or C₁-C₆ alkyl; and

R⁹ is hydrogen or C₁-C₄ alkyl.

30

15. A compound as claimed in claim 14 wherein, R¹, R³ and R⁴ are hydrogen,

while R² is halo.

16. A compound as claimed in claim 15 wherein R² is fluoro.

5 17. A compound as claimed in any one of claims 14 to 16, wherein at least one of R⁵ and R⁶ is hydrogen.

18. A compound as claimed in any one of claims 13 to 17 wherein R⁷ is methyl.

10 19. A compound as claimed in any one of claims 13 to 18 wherein R⁸ is phenyl, naphthalenyl, quinolinyl, quinoxaliny, thiazolyl, biphenyl or benzothiazolyl, any of which is optionally substituted by a substituent as defined in claim 1.

15 20. A compound as claimed in claim 19 wherein the R⁸ moiety is phenyl substituted at the 4-position or naphthalen-2-yl, quinolin-2-yl, quinoxalin-2-yl, thiazol-2-yl or benzothiazol-2-yl, any of which is optionally substituted with one or more of the substituents defined in claim 1.

20 21. A compound as claimed in claim 19 or claim 20 wherein the R⁸ moiety is substituted with one or more substituents selected from halo, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₁-C₄ alkylsulfonyl and hydroxy.

25 22. A compound as claimed in claim 21, wherein the R⁸ moiety is substituted with one or more substituents chosen from chloro, fluoro, methyl, ethyl, t-butyl, trifluoromethyl, methoxy, methanesulfonyl and hydroxy.

23. {3-[1-(4-Chloro-phenyl)-ethyl]-5-fluoro-2-methyl-indol-1-yl}-acetic acid
{5-Fluoro-2-methyl-3-[1-(4-trifluoromethyl-phenyl)-ethyl]-indol-1-yl}-acetic acid
{3-[1-(4-*tert*-Butyl-phenyl)-ethyl]-5-fluoro-2-methyl-indol-1-yl}-acetic acid
30 {5-Fluoro-3-[1-(4-methanesulfonyl-phenyl)-ethyl]-2-methyl-indol-1-yl}-acetic acid
[5-Fluoro-2-methyl-3-(1-naphthalen-2-yl-ethyl)-indol-1-yl]-acetic acid

- (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid
 (5-Fluoro-2-methyl-3-naphthalen-2-ylmethyl-indol-1-yl)-acetic acid
 [5-Fluoro-3-(8-hydroxy-quinolin-2-ylmethyl)-2-methyl-indol-1-yl]-acetic acid
 (5-Fluoro-2-methyl-3-quinoxalin-2-ylmethyl-indol-1-yl)-acetic acid
 5 [5-Fluoro-3-(4-methoxy-benzyl)-2-methyl-indol-1-yl]-acetic acid
 (5-Fluoro-2-methyl-3-thiazol-2-ylmethyl-indol-1-yl)-acetic acid ethyl ester
 [3-(4-Chloro-benzyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid
 (3-Benzothiazol-2-ylmethyl-5-fluoro-2-methyl-indol-1-yl)-acetic acid
 [5-Fluoro-2-methyl-3-(4-trifluoromethyl-benzyl)-indol-1-yl]-acetic acid
 10 [5-Fluoro-2-methyl-3-(4-*tert*-butyl-benzyl)-indol-1-yl]-acetic acid
 (3-Biphenyl-4-ylmethyl-5-fluoro-2-methyl-indol-1-yl)-acetic acid
 [5-Fluoro-3-(4-methanesulfonyl-benzyl)-2-methyl-indol-1-yl]-acetic acid
 [5-Fluoro-3-(6-fluoro-quinolin-2-ylmethyl)-2-methyl-indol-1-yl]-acetic acid
 (\pm)-3-(1-Benzothiazol-2-yl-ethyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid
 15 (2-Methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid
 (5-Chloro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid;
 or the C₁-C₆ alkyl, aryl, (CH₂)_mOC(=O)C₁-C₆alkyl, (CH₂)_mN(R¹³)₂,
 CH((CH₂)_mO(C=O)R¹⁴)₂ esters of any of the above; wherein
 m is 1 or 2;
 20 R¹³ is hydrogen or methyl;
 R¹⁴ is C₁-C₁₈ alkyl.

24. A process for the preparation of a compound of general formula (I) as defined
 in any one of claims 13 to 23, the process comprising the hydrolysis of a compound
 25 of general formula (II) as defined in claim 13 and wherein R¹² is C₁-C₆ alkyl.

25. A compound as claimed in any one of claims 13 to 23 for use in medicine,
 particularly for use in the treatment or prevention of diseases and conditions
 mediated by PGD₂ at the CRTH2 receptor.

30

26. A compound as claimed in any one of claims 13 to 23 for use in the treatment

or prevention of allergic asthma, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity (including contact dermatitis), conjunctivitis, especially allergic conjunctivitis, eosinophilic bronchitis, food allergies, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis and Crohn's disease, mastocytosis and also other PGD₂-mediated diseases, for example autoimmune diseases such as hyper IgE syndrome and systemic lupus erythematus, psoriasis, acne, multiple sclerosis, allograft rejection, reperfusion injury, chronic obstructive pulmonary disease, as well as rheumatoid arthritis, psoriatic arthritis and osteoarthritis.

10

27. A pharmaceutical composition comprising a compound as claimed in any one of claims 13 to 23 together with a pharmaceutical excipient or carrier.

15

28. A composition as claimed in claim 27 formulated for oral, nasal, bronchial or topical administration.

20

29. A composition as claimed in claim 27 or claim 28 containing one or more additional active agents useful in the treatment of diseases and conditions mediated by PGD₂ at the CRTH2 receptor.

25

30. A composition as claimed in claim 29, wherein the additional active agents are selected from:

β₂ agonists such as salmeterol;

corticosteroids such as fluticasone;

25

antihistamines such as loratidine;

leukotriene antagonists such as montelukast;

anti-IgE antibody therapies such as omalizumab;

anti-infectives such as fusidic acid (particularly for the treatment of atopic dermatitis);

30

anti-fungals such as clotrimazole (particularly for the treatment of atopic dermatitis); immunosuppressants such as tacrolimus and particularly pimecrolimus in the case of

inflammatory skin disease;
other antagonists of PGD₂ acting at other receptors such as DP antagonists;
inhibitors of phosphodiesterase type 4 such as cilonilast;
drugs that modulate cytokine production such as inhibitors of TNF α converting
5 enzyme (TACE);
drugs that modulate the activity of Th2 cytokines IL-4 and IL-5 such as blocking
monoclonal antibodies and soluble receptors;
PPAR- γ agonists such as rosiglitazone;
5-lipoxygenase inhibitors such as zileuton.

10

31. A process for the preparation of a pharmaceutical composition as claimed in
any one of claims 27 to 30 comprising bringing a compound as claimed in claim 14
or claim 15 in conjunction or association with a pharmaceutically or veterinarily
acceptable carrier or vehicle.

15

32. A product comprising a compound as claimed in any one of claims 13 to 23
and one or more of the agents listed in claim 30 as a combined preparation for
simultaneous, separate or sequential use in the treatment of a disease or condition
mediated by the action of PGD₂ at the CRTH2 receptor.

20

33. The use as claimed in any one of claims 1 to 12, wherein the agent also
comprises an additional active agent useful for the treatment of diseases and
conditions mediated by PGD₂ at the CRTH2 and/or DP receptor.

25

34. The use as claimed in claim 33, wherein the additional active agent is one of
the agents listed in claim 30.

INTERNATIONAL SEARCH REPORT

 Int. Application No
 PCT/EP2004/004417

A. CLASSIFICATION OF SUBJECT MATTER

 IPC 7 A61K31/404 A61K31/428 A61K31/426 A61K31/4709 A61K31/498
 A61P11/02 A61P11/06 A61P17/00 A61P19/02 A61P37/00
 A61P43/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, PAJ, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 859 692 A (BERNSTEIN PETER R ET AL) 22 August 1989 (1989-08-22) abstract column 1, line 5 - column 11, line 6 column 19, line 29 - column 20, line 16; examples 120,121	1-3,6, 8-11,13, 14,17, 19-22, 24-34
X	US 4 273 782 A (CROSS PETER E ET AL) 16 June 1981 (1981-06-16) abstract column 1, lines 5-15; examples 10,23 ----- -/--	1-3,6, 13,14, 17, 24-29,31

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

18 February 2005

Date of mailing of the international search report

04/03/2005

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

A. Jakobs

INTERNATIONAL SEARCH REPORT

Int: nal Application No
PCT/GB2004/004417

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3 557 142 A (BELL MALCOLM R) 19 January 1971 (1971-01-19) abstract; examples 71,72 -----	13, 14, 17-22, 25-29, 31
X	WO 99/50268 A (JONES JOHN HOWARD ;ZANDT MICHAEL C VAN (US); GUNN DAVID (US); JONE) 7 October 1999 (1999-10-07) cited in the application abstract; claims 19-26, 28-35, 42-46, 50 * Scheme A * page 6, lines 4-19; examples 1-6, 8-13, 20-25, 27-32 -----	13-28, 31
X	WO 01/51489 A (BOYD MARCELLE ;ROBINSON DALE (US); INST FOR PHARMACEUTICAL DISCOV) 19 July 2001 (2001-07-19) cited in the application abstract page 1, lines 17-27 page 5, lines 21-24 examples 1-6, 8-13, 20-25, 27-32 -----	13-22, 24-34
X	WO 01/64205 A (ZANDT MICHAEL VAN ;SREDY JANET (US); INST FOR PHARMACEUTICAL DISCO) 7 September 2001 (2001-09-07) abstract page 20, line 9 - page 22, line 18 -----	1-22, 24-34
X	WO 00/32180 A (JACOT JORGE ;SREDY JANET (US); INST FOR PHARMACEUTICAL DISCOV (US)) 8 June 2000 (2000-06-08) abstract; claims 1-56; examples 1-6, 8-13, 20-25, 27-32 -----	1-22, 24-34
P, A	WO 03/097598 A (HIRAMATSU YOSHIHARU ;TANIMOTO NORIHIKO (JP); SHIONOGI & CO (JP); I) 27 November 2003 (2003-11-27) the whole document -----	1
X	MATASSA V G ET AL: "Evolution of a Series of Peptidoleukotriene Antagonists: Synthesis and Structure/Activity Relationships of 1,3,5-Substituted Indoles and Indazoles" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 6, no. 33, 1990, pages 1781-1790, XP002077392 ISSN: 0022-2623 * compound 22 * the whole document ----- -/--	1, 3, 8-11, 13-15, 17, 19, 20, 22, 25-28, 31

INTERNATIONAL SEARCH REPORT

Int. Application No
PC1/GB2004/004417

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CROSS, PETER E. ET AL: "Selective thromboxane synthetase inhibitors. 2. 3-(1H-Imidazol-1-ylmethyl)-2-methyl-1H-indole-1-propanoic acid and analogs." JOURNAL OF MEDICINAL CHEMISTRY (1986), 29(3), 342-6, 1986, XP001190895 page 342, column 2, paragraph 4 -----	1-3,6, 13,14, 17, 24-28,31
X	JP 2001 247570 A (JAPAN TOBACCO INC) 11 September 2001 (2001-09-11) the whole document -----	13-17, 19-22, 25,27, 28,31
A	EP 0 539 117 A (LILLY INDUSTRIES LTD) 28 April 1993 (1993-04-28) abstract; example 16 page 8, line 57 - page 9, line 4 -----	1
A	US 4 363 912 A (DICKINSON ROGER P ET AL) 14 December 1982 (1982-12-14) abstract; example 1 -----	1
A	EP 0 574 174 A (LILLY CO ELI) 15 December 1993 (1993-12-15) abstract; example 24 -----	1
A	KUMAR, SUBODH ET AL: "Novel indium-mediated ternary reactions between indole-3-carboxaldehydes, allyl bromides, and enamines: facile synthesis of bisindolyl- and indolyl-heterocyclic alkanes" TETRAHEDRON LETTERS , 44(10), 2101-2104 CODEN: TELEAY; ISSN: 0040-4039, 3 March 2003 (2003-03-03), XP002318427 the whole document -----	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

In International Application No
PCT/GB2004/004417

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4859692	A	22-08-1989	AR 242569 A1	30-04-1993
			AT 70053 T	15-12-1991
			AU 596582 B2	10-05-1990
			AU 5616486 A	23-10-1986
			BG 60471 B2	28-04-1995
			CA 1340567 C	01-06-1999
			CN 86103278 A ,B	17-12-1986
			CS 9103997 A3	16-09-1992
			CY 1705 A	14-01-1994
			DD 251348 A5	11-11-1987
			DE 3682698 D1	16-01-1992
			DK 173486 A	18-10-1986
			EP 0199543 A2	29-10-1986
			ES 8802220 A1	01-07-1988
			ES 8802493 A1	16-10-1988
			ES 8802494 A1	16-10-1988
			ES 8802023 A1	01-06-1988
			ES 8801787 A1	01-05-1988
			FI 861601 A ,B,	18-10-1986
			GR 861008 A1	11-08-1986
			HK 120994 A	11-11-1994
			HU 40623 A2	28-01-1987
			IE 59140 B1	12-01-1994
			IL 78569 A	09-02-1990
			JP 2033766 C	19-03-1996
			JP 6279404 A	04-10-1994
			JP 7042270 B	10-05-1995
			JP 1955810 C	28-07-1995
			JP 6067904 B	31-08-1994
			JP 62093274 A	28-04-1987
			KR 9004384 B1	23-06-1990
			LU 90070 A9	23-07-1997
			NO 861481 A ,B,	20-10-1986
			NZ 215850 A	27-03-1990
			PH 26763 A	28-09-1992
			PT 82389 A ,B	01-05-1986
			US 5391758 A	21-02-1995
			US 5440035 A	08-08-1995
			US 5030643 A	09-07-1991
			US 5583152 A	10-12-1996
			US 5179112 A	12-01-1993
			US 5338734 A	16-08-1994
			ZA 8602858 A	28-01-1987
			ZM 4486 A1	29-10-1986
			ZW 8786 A1	04-11-1987
			AT 74127 T	15-04-1992
			AU 595839 B2	12-04-1990
			AU 6398586 A	30-04-1987
			CA 1336192 C	04-07-1995
			DE 3684549 D1	30-04-1992
US 4273782	A	16-06-1981	AR 227015 A1	15-09-1982
			AT 375366 B	25-07-1984
			AT 125780 A	15-12-1983
			AT 375932 B	25-09-1984
			AT 290683 A	15-02-1984
			AU 516957 B2	02-07-1981
			AU 5623180 A	11-09-1980

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB2004/004417

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4273782	A		BE 882113 A1	08-09-1980
			CA 1120479 A1	23-03-1982
			CH 649546 A5	31-05-1985
			CS 253702 B2	17-12-1987
			DD 149525 A5	15-07-1981
			DE 3008632 A1	16-10-1980
			DK 42580 A ,B,	08-09-1980
			ES 8104278 A1	01-07-1981
			ES 8205789 A1	01-11-1982
			FI 800672 A ,B,	08-09-1980
			FR 2450832 A1	03-10-1980
			GB 2045244 A ,B	29-10-1980
			GR 67237 A1	25-06-1981
			HK 89884 A	23-11-1984
			HU 184727 B	29-10-1984
			IE 49542 B1	30-10-1985
			IL 59524 A	30-11-1982
			IT 1218420 B	19-04-1990
			JP 55133380 A	17-10-1980
			JP 61041513 B	16-09-1986
			KE 3467 A	09-11-1984
			KR 8500760 B1	25-05-1985
			LU 82224 A1	06-06-1980
			MY 28585 A	31-12-1985
			NL 8001351 A ,C	09-09-1980
			NO 800650 A ,B,	08-09-1980
			NZ 193052 A	06-07-1984
			PH 15198 A	17-09-1982
			PL 222470 A1	01-12-1980
			PT 70914 A	01-04-1980
			SE 440778 B	19-08-1985
			SE 8001736 A	08-09-1980
			SG 67284 G	15-03-1985
			SU 1277894 A3	15-12-1986
			YU 61480 A1	31-12-1983
			ZA 8001328 A	25-03-1981
US 3557142	A	19-01-1971	BE 728675 A	20-08-1969
			CH 507238 A	15-05-1971
			DE 1908541 A1	18-09-1969
			FR 2002284 A5	17-10-1969
			GB 1206915 A	30-09-1970
			JP 48043740 B	20-12-1973
			NL 6902641 A	22-08-1969
			SE 350259 B	23-10-1972
			US 3843683 A	22-10-1974
WO 9950268	A	07-10-1999	AT 269861 T	15-07-2004
			AU 774929 B2	15-07-2004
			AU 3459599 A	18-10-1999
			BG 104819 A	31-05-2001
			BR 9909358 A	12-12-2000
			CA 2383983 A1	07-10-1999
			CN 1296485 T	23-05-2001
			DE 69918278 D1	29-07-2004
			EE 200000573 A	15-04-2002
			EP 1066283 A2	10-01-2001
			HU 0101672 A2	29-04-2002

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Patent Application No
PCT/GB2004/004417

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9950268 A		ID 27884 A	03-05-2001
		JP 3494990 B2	09-02-2004
		JP 2002509931 T	02-04-2002
		JP 2003155274 A	27-05-2003
		NO 20004900 A	17-10-2000
		NZ 507172 A	31-10-2003
		OA 11622 A	16-09-2004
		PL 348244 A1	20-05-2002
		SK 7522001 A3	05-02-2002
		TR 200002869 T2	21-12-2000
		WO 9950268 A2	07-10-1999
		US 2003018053 A1	23-01-2003
		US 6214991 B1	10-04-2001
		US 2001016661 A1	23-08-2001
		US 2004235933 A1	25-11-2004
		ZA 200005577 A	11-02-2002
WO 0151489 A	19-07-2001	AU 3278501 A	24-07-2001
		WO 0151489 A2	19-07-2001
		US 2001044437 A1	22-11-2001
WO 0164205 A	07-09-2001	AU 3871801 A	12-09-2001
		WO 0164205 A2	07-09-2001
		US 2003171405 A1	11-09-2003
		US 2001041722 A1	15-11-2001
WO 0032180 A	08-06-2000	AT 265210 T	15-05-2004
		AU 770925 B2	11-03-2004
		AU 2161600 A	19-06-2000
		BG 105531 A	31-12-2001
		BR 9915882 A	21-08-2001
		CA 2385845 A1	08-06-2000
		CN 1368883 T	11-09-2002
		CZ 20011864 A3	13-03-2002
		DE 69916881 D1	03-06-2004
		DE 69916881 T2	03-02-2005
		EE 200100296 A	17-02-2003
		EP 1135124 A2	26-09-2001
		HU 0104953 A2	29-07-2002
		ID 30037 A	01-11-2001
		JP 2002531398 T	24-09-2002
		NO 20012690 A	27-07-2001
		PL 349016 A1	17-06-2002
		SK 7352001 A3	04-06-2002
		TR 200101539 T2	21-12-2001
		TW 584560 B	21-04-2004
		WO 0032180 A2	08-06-2000
		US 2003216452 A1	20-11-2003
		US 6555568 B1	29-04-2003
		ZA 200104126 A	21-05-2002
WO 03097598 A	27-11-2003	EP 1505061 A1	09-02-2005
		WO 03097598 A1	27-11-2003
JP 2001247570 A	11-09-2001	NONE	
EP 0539117 A	28-04-1993	AT 163933 T	15-03-1998
		CA 2081133 A1	25-04-1993

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC I/GB2004/004417

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0539117 A		DE 69224697 D1	16-04-1998
		DE 69224697 T2	16-07-1998
		DK 539117 T3	28-09-1998
		EP 0539117 A1	28-04-1993
		ES 2113927 T3	16-05-1998
		JP 5345778 A	27-12-1993
		US 5410061 A	25-04-1995
US 4363912 A	14-12-1982	AR 229110 A1	15-06-1983
		AU 525296 B2	28-10-1982
		AU 7848881 A	24-06-1982
		CA 1143737 A1	29-03-1983
		CS 228527 B2	14-05-1984
		DD 202290 A5	07-09-1983
		DE 3167879 D1	31-01-1985
		DK 552581 A	16-06-1982
		EP 0054417 A1	23-06-1982
		ES 8308872 A1	16-12-1983
		FI 814003 A	16-06-1982
		GR 76355 A1	06-08-1984
		IE 51949 B1	29-04-1987
		JP 57181082 A	08-11-1982
		NO 814264 A	16-06-1982
		PH 17576 A	01-10-1984
		PL 234253 A1	23-05-1983
		PT 74123 A ,B	01-01-1982
		YU 293481 A1	31-10-1984
		ZA 8108665 A	27-10-1982
EP 0574174 A	15-12-1993	US 5612360 A	18-03-1997
		AT 247107 T	15-08-2003
		AU 661396 B2	20-07-1995
		AU 3998693 A	09-12-1993
		CA 2097460 A1	04-12-1993
		CN 1101908 A	26-04-1995
		CZ 9301045 A3	19-01-1994
		DE 69333138 D1	18-09-2003
		DE 69333138 T2	09-06-2004
		DK 574174 T3	08-12-2003
		EP 0574174 A2	15-12-1993
		ES 2204898 T3	01-05-2004
		FI 932518 A	04-12-1993
		HU 64330 A2	28-12-1993
		JP 6080666 A	22-03-1994
		MX 9303263 A1	01-12-1993
		NO 932004 A	06-12-1993
		NZ 247770 A	26-10-1995
		PL 299177 A1	07-02-1994
		PT 574174 T	31-12-2003
		US 5556981 A	17-09-1996
		US 5693633 A	02-12-1997
		US 5569768 A	29-10-1996